Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy (Q45329433)

13 December 2017

Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy (English)

1 reference

13 December 2017

0 references

0 references

1 reference

1 reference

7

1 reference

13 December 2017

S Wheeler

1

1 reference

13 December 2017

K Moore

2

1 reference

13 December 2017

C W Forsberg

3

1 reference

13 December 2017

K Riley

4

1 reference

13 December 2017

J S Floyd

5

1 reference

13 December 2017

N L Smith

6

1 reference

13 December 2017

25 June 2013

1 reference

13 December 2017

1 reference

13 December 2017

56

1 reference

13 December 2017

9

1 reference

13 December 2017

1934-1943

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-013-2958-1

13 December 2017

0 references

cites work

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Effect of glyburide-metformin combination tablet in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Rosiglitazone and the risk of adverse cardiovascular outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

A primer and comparative review of major US mortality databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Multiple imputation: a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Smoking prevalence among US veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2958-1

Confounding by indication

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23797633

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23797633

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23797633

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00125-013-2958-1

1 reference

Dimensions Publication ID

13 December 2017

0 references

1 reference